Related Experiment Video
Updated: Jun 12, 2025
Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells
Published on: June 20, 2018
Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis
Olivia Boyer1, Mélissa Ould Rabah2, Evgenia Preka3,4
1Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et l'Adulte (MARHEA), Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (APHP), Institut Imagine, Laboratory of Hereditary Kidney Diseases, INSERM U1163, Université Paris Cité, 149 Rue de Sèvres, 75015, Paris, France. olivia.boyer@aphp.fr.
Insights
Distal renal tubular acidosis (dRTA) treatment is improving with a new extended-release alkali therapy. This novel formulation enhances patient adherence and reduces complications associated with metabolic acidosis.
Area of Science:
- Nephrology
- Genetics
- Pharmacology
Background:
- Distal renal tubular acidosis (dRTA) involves impaired proton secretion, leading to metabolic acidosis, hypokalemia, and hypercalciuria.
- Inherited dRTA links to mutations in five genes; acquired forms arise from autoimmune diseases or drugs.
- Complications include kidney stones, nephrocalcinosis, reduced GFR, bone demineralization, and growth failure.
Purpose of the Study:
- To evaluate the efficacy and safety of a novel extended-release alkali formulation for distal renal tubular acidosis (dRTA).
- To address challenges with traditional dRTA treatments, focusing on improved patient adherence and reduced gastrointestinal discomfort.
Main Methods:
- Review of recent studies and European Medicine Agency (EMA) approval data for the investigational drug ADV7103.
- Analysis of ADV7103's composition: extended-release potassium citrate and potassium bicarbonate.
Main Results:
- ADV7103, an extended-release formulation of potassium citrate and bicarbonate, has received EMA approval for dRTA treatment.
- Recent studies indicate ADV7103's efficacy and safety as a potential first-line therapy for dRTA.
Conclusions:
- The novel extended-release formulation ADV7103 offers a promising advancement in managing distal renal tubular acidosis.
- Improved adherence and tolerability compared to traditional alkali therapies may reduce long-term renal complications and improve patient outcomes.
Abstract:
Distal renal tubular acidosis (dRTA) is characterized by a primary defect in proton secretion by α-intercalated cells of the collecting duct, leading to impaired urine acidification and resulting in metabolic acidosis, hypokalemia, and hypercalciuria. Inherited forms of dRTA are currently associated with variants in five genes (SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, and WDR72), each being associated with specific extra-renal manifestations. Acquired forms can result from autoimmune diseases or drug side effects. Classical complications include nephrolithiasis, nephrocalcinosis, reduced glomerular filtration rate (GFR), bone demineralization, and growth failure. Treatment focuses on correcting the acid-base imbalance through alkali supplementation (potassium, sodium, or magnesium bicarbonate or citrate) to reduce renal disease progression and promote normal growth and mineralization. Traditional treatments (alkali and potassium supplementation) often suffer from poor adherence due to frequent day and night administrations, gastrointestinal discomfort, and unpleasant taste. A novel investigational drug, ADV7103, which contains potassium citrate and potassium bicarbonate in an extended-release formulation, has recently been approved by the European Medicine Agency (EMA) for dRTA. Recent studies support its use as a first-line treatment, given its efficacy and safety profile.
Related Concept Videos
01:20Acute Kidney Injury V: Interprofessional Care
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
01:29Renal Regulation of Acid-Base Balance
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
01:28Renal Drug Excretion: Tubular Secretion
01:28Chronic Kidney Disease III: Interprofessional Care
01:24Renal Tubule and Collecting Duct
Proximal Convoluted Tubule (PCT):
The PCT is the initial segment of the renal tubule, extending from the Bowman's capsule that encloses the glomerulus. Its convoluted structure and microvilli-lined cells increase the surface area for reabsorption. The PCT reabsorbs glucose, amino acids, sodium, and water from the filtrate, ensuring essential...